Rheumatoid Arthritis
Dr. John Cush RheumNow
3 years 4 months ago
GLORIA Study Pred vs PBO in >65yrs RA x 2 years. 451 Pts & DAS28 4.5. 79% on DMARDs (14% biologics)
Upside: Lower DAS28 -0.37 & less Xray progression -1.7 Sharp units
Downside: 24% more AE (mild infxns), signif.small lowering of lumbar BMD -1%
You Decide
https://t.co/RRq0WcFsXz https://t.co/xLxjPPSMhh
Dr. John Cush RheumNow
3 years 4 months ago
CV risk factors not equal when considering magnitude of risk
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
https://t.co/LHZTVZh4AK https://t.co/2SlxrG7UpQ
Dr. John Cush RheumNow
3 years 4 months ago
Can we stop RA before it happens?
Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent RA occurring in at-risk individuals.
https://t.co/vU4tRr7UJh https://t.co/cikU9pwaiT
Dr. John Cush RheumNow
3 years 4 months ago
Watch: RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
https://t.co/Lp25lP6ZZY https://t.co/wd5GCbaCLR
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media…
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
Dr. John Cush RheumNow
3 years 4 months ago
Video: Residual Pain in RA
Dr. Maxime Dougados discusses OP0052 at #EULAR2022.
https://t.co/gu1Svegss8 https://t.co/G1rRizG9gW
Dr. John Cush RheumNow
3 years 4 months ago
Canadian study of 50,883 RA pts shows only 58% saw a rheumatologist yearly for 5 yrs. If >65 yrs, Rheum care assoc w/ DMARD use in 82%; but was only 31% if not under Rheum care. Worse rheum retention with age >81, male, lower SES, older Rheums https://t.co/xUxWaksgsE
Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent rheumatoid arthritis occurring in at-risk individuals. While it is often a point of substantive discussion at EULAR, this year’s meeting in Copenhagen provided further data on how therapy might useful before patients develop rheumatoid arthritis (RA), particularly for those at particularly high risk.
Dr. John Cush RheumNow
3 years 4 months ago
FDA approved another rituximab biosimilar, rituximab-arrx (Riabni) (from Amgen), for use w/ MTX in active RA. Riabni is not currently approved for B-cell NHL, B-cell leukemia, MPA, or GPA. or pemphigus vulgaris (RTX is an orphan drug) https://t.co/Htk0xBx63X https://t.co/ep1L3YO9hl
Poster Hall